Clinical safety rating: safe
Human studies have proved safety
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
| Metabolism | Piperacillin undergoes minor hepatic metabolism; tazobactam is metabolized to a minor inactive metabolite. Both are primarily excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite. |
| Half-life | Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD). |
| Protein binding | Piperacillin: ~30% bound to albumin; Tazobactam: ~30% bound to albumin. |
| Volume of Distribution | Piperacillin: ~0.18-0.3 L/kg; Tazobactam: ~0.2-0.3 L/kg. Distributes widely into tissues, including lung, kidney, bile, peritoneal fluid, and inflamed tissues. |
| Bioavailability | IV only; oral bioavailability negligible (not orally administered). |
| Onset of Action | IV: Immediate; peak plasma concentrations at end of infusion. |
| Duration of Action | Administered every 6-8 hours (or continuous infusion) due to short half-life; clinical effect persists for dosing interval. In renal impairment, dosing interval extended. |
| Molecular Weight | Tazobactam: 300.3 Da; Piperacillin: 517.5 Da; combination: 817.8 Da. |
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
| Renal impairment | CrCl 20-40 mL/min: 2.25 g IV every 6 hours; CrCl <20 mL/min: 2.25 g IV every 8 hours; hemodialysis: 2.25 g IV every 12 hours, plus 0.75 g after dialysis. |
| Liver impairment | No dosage adjustment required for hepatic impairment. Use caution in patients with hepatic encephalopathy or severe hepatic dysfunction. |
| Pediatric use | Infants and children: 100 mg piperacillin/kg/dose IV every 6-8 hours (max 4 g piperacillin per dose); for pseudomonal infections, up to 200 mg/kg/dose IV every 6 hours. |
| Geriatric use | Start at the lower end of dosing; adjust primarily based on renal function. Monitor renal function closely and modify dose according to creatinine clearance. |
| 1st trimester | Crosses placenta; animal studies show no teratogenicity; human data limited but considered low risk; use if benefit outweighs risk. |
| 2nd trimester | Safe, widely used for infections during pregnancy; no known fetal harm. |
| 3rd trimester | Safe, used for intrapartum prophylaxis; avoid prolonged use near delivery due to possible alteration of neonatal gut flora. |
Clinical note
Broad-spectrum beta-lactam/beta-lactamase inhibitor combination used IV for polymicrobial serious infections in pregnancy including chorioamnionitis, complicated UTI/pyelonephritis, and postpartum endometritis. No evidence of teratogenicity. Commonly used in obstetric practice for serious infections requiring broad coverage.
| Placental transfer | Crosses placenta; achieves therapeutic concentrations in fetal serum. |
| Breastfeeding | Excreted into breast milk in low concentrations (<1% of maternal dose); considered compatible with breastfeeding; monitor infant for diarrhea and rash. |
■ FDA Black Box Warning
No FDA black box warnings.
| Serious Effects |
Hypersensitivity to penicillins or beta-lactamase inhibitorsHistory of severe allergic reaction to cephalosporins or carbapenems
| Precautions | Hypersensitivity reactions including anaphylaxis, Clostridioides difficile-associated diarrhea, Hematologic toxicity (neutropenia, thrombocytopenia) with prolonged therapy, Renal impairment requiring dose adjustment, Electrolyte disturbances (hypokalemia), Neuromuscular irritability or seizures with high doses or renal failure |
| Food/Dietary | No significant food interactions; take with or without food. Avoid alcohol during therapy. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is generally acceptable for serious infections. |
| Fetal Monitoring | Monitor maternal renal function, CBC with differential, coagulation parameters, and signs of hypersensitivity. In neonates exposed in utero, monitor for potential antibiotic-induced diarrhea or candidiasis. |
| Fertility Effects | No evidence of impaired fertility from animal studies. No human data on fertility effects. |
| Piperacillin-tazobactam (Zosyn) exhibits time-dependent killing; optimal efficacy requires frequent dosing (every 6 hours) with extended infusion (4 hours) for critically ill patients. Adjust dose for renal impairment; CrCl <20 mL/min: max 2.25 g every 8 hours. Monitor for bleeding risk due to platelet dysfunction at high doses. Contains sodium (2.79 mEq per gram of piperacillin); caution in heart failure. Do not co-administer with aminoglycosides in same IV line; use separate sites. |
| Patient Advice | Take this medication exactly as prescribed; do not skip doses even if feeling better. · Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately. · This drug may cause diarrhea, nausea, or headache; contact your doctor if severe or persistent. · Inform your doctor if you have kidney disease, heart failure, or bleeding disorders. · Avoid alcohol while taking this medication to reduce risk of adverse effects. |